Venus Medtech (Hangzhou) Inc.
VMTHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.00 | -0.02 |
| FCF Yield | 0.00% | -163.70% | 112.56% | -1,448.07% |
| EV / EBITDA | -8.21 | -0.23 | -0.29 | -0.41 |
| Quality | ||||
| ROIC | -4.70% | -4.53% | -5.64% | -6.10% |
| Gross Margin | 73.74% | 77.46% | 78.78% | 79.72% |
| Cash Conversion Ratio | – | 0.11 | -0.40 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.17% | 23.62% | 35.25% | 56.72% |
| Free Cash Flow Growth | 100.00% | -246.05% | 107.96% | -26.38% |
| Safety | ||||
| Net Debt / EBITDA | -1.76 | -0.16 | -0.08 | -0.25 |
| Interest Coverage | -19.12 | -8.45 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.55 | 0.40 | 0.42 |
| Cash Conversion Cycle | 215.84 | 236.90 | 260.10 | 259.82 |